ArticleScientific reports2025
Lapachol interferes with the cell cycle and inhibits proliferation and migration of bladder tumor cells with effects on ncRNA expression.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Silk Fibroin-Stabilized Lapachol Microemulsion Enhances Antiglioma Activity In Vitro.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is one of the most prevalent cancers worldwide. Lapachol is a natural compound with antiproliferative effects, but its activity in bladder cancer cells has not yet been evaluated. Cytotoxic activity was assessed using the MTT assay, while long-term effects were evaluated through the clonogenic assay. Cell migration was assessed by the scratch assay, and cell cycle progression was analyzed via flow cytometry. The expression of the JHDM1D gene and the long non-coding RNAs (lncRNAs) JHDM1D-AS1, SBF2-AS1, and RP11-36E7.4 was investigated. Treatment resulted in a dose- and time-dependent inhibition of cell viability, accompanied by a significant reduction in clonogenic survival in all cell lines. Lapachol impaired cell migration, with RT4 cells showing the greatest sensitivity. Cell cycle analysis revealed a significant increase in the sub-G1 cell population, indicative of apoptosis, and a concomitant decrease in the G0/G1 phase. Molecular analysis revealed modulation of lncRNA expression in a cell-line-specific manner. In RT4 cells, there was a downregulation of SBF2-AS1 expression. In J82 cells, a decrease in JHDM1D-AS1 and an increase in RP11-36E7.4 expression were observed. These findings suggest that lapachol exerts significant antiproliferative effects on bladder cancer cells through mechanisms involving cell cycle arrest, apoptosis induction, and modulation of lncRNA expression, supporting its potential for bladder cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.